Hikma Pharmaceuticals PLC (GB:HIK)
LSE:HIK

Hikma Pharmaceuticals (HIK) Share Price & Analysis

10 Followers

HIK Stock Chart & Stats

Day’s Range0p - 0p
52-Week Range1,153.82p - 1,915.50p
Previous Close1,803p
Volume20.39K
Average Volume (3M)547.15K
Market Cap
£3.98B
Enterprise Value479.01B
Total Cash (Recent Filing)$292.00M
Total Debt (Recent Filing)$1.28B
Price to Earnings (P/E)26.5
Beta0.74
Aug 03, 2023
0.42 (0.02%)
Share Statistics
EPS (TTM)0.65
Shares Outstanding220,235,852
10 Day Avg. Volume515,666
30 Day Avg. Volume547,154
Standard Deviation0.11
R-Squared0.00655
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)390.26
Price to Sales (P/S)431.29
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit386.92
Enterprise Value/EbitdaN/A
Forecast
Price Target Upside10.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4


Hikma Pharmaceuticals News


Financials

Annual

HIK FAQ

What was Hikma Pharmaceuticals PLC’s price range in the past 12 months?
Hikma Pharmaceuticals PLC lowest share price was 1153.82p and its highest was 1915.50p in the past 12 months.
    What is Hikma Pharmaceuticals PLC’s market cap?
    Currently, no data Available
    When is Hikma Pharmaceuticals PLC’s upcoming earnings report date?
    Hikma Pharmaceuticals PLC’s upcoming earnings report date is Aug 03, 2023 which is in 60 days.
      How were Hikma Pharmaceuticals PLC’s earnings last quarter?
      Hikma Pharmaceuticals PLC released its earnings results on Feb 23, 2023. The company reported 0.708p earnings per share for the quarter, beating the consensus estimate of 0.622p by 0.085p.
        Is Hikma Pharmaceuticals PLC overvalued?
        According to Wall Street analysts Hikma Pharmaceuticals PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Hikma Pharmaceuticals PLC pay dividends?
          Hikma Pharmaceuticals PLC pays a Annually dividend of 30.77p which represents an annual dividend yield of 2.54%. See more information on Hikma Pharmaceuticals PLC dividends here
            What is Hikma Pharmaceuticals PLC’s EPS estimate?
            Hikma Pharmaceuticals PLC’s EPS estimate is £0.76.
              How many shares outstanding does Hikma Pharmaceuticals PLC have?
              Hikma Pharmaceuticals PLC has 220,988,500 shares outstanding.
                What happened to Hikma Pharmaceuticals PLC’s price movement after its last earnings report?
                Hikma Pharmaceuticals PLC reported an EPS of 0.708p in its last earnings report, beating expectations of 0.622p. Following the earnings report the stock price went down -2.025%.
                  Which hedge fund is a major shareholder of Hikma Pharmaceuticals PLC?
                  Currently, no hedge funds are holding shares in GB:HIK

                  ---

                  Hikma Pharmaceuticals Stock Smart Score

                  The Hikma Pharmaceuticals Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Hikma Pharmaceuticals PLC

                  Founded in the Middle East and with headquarters in London, Hikma manufactures generic and in-licensed pharmaceuticals. The firm operates in three segments: injectables, generics, branded, and other, which comprise most of the company's revenue at about 41%, 33%, and 26%, respectively. About 62%, 33%, and 6% of Hikma's sales are based in the U.S., Middle East, North Africa, and Europe, and Other.

                  ---

                  Top 5 ETFs holding HIK

                  Name
                  Market Value
                  Smart Score
                  iShares MSCI United Kingdom ETF
                  $4.77M
                  8
                  UBS (Irl) ETF Plc - MSCI United Kingdom IMI Socially Responsible UCITS ETF EUR
                  $3.61M
                  8
                  UBS (Irl) ETF Plc-MSCI United Kingdom IMI Socially Responsible CHF
                  $3.61M
                  8
                  UBS ETF MSCI UK Shs -A- Distribution
                  $3.02M
                  8
                  UBS (Lux) Fund Solutions SICAV - MSCI United Kingdom UCITS ETF A- Capitalisation
                  $2.94M
                  8
                  Up to five ETFs with an Outperform Smart Score that hold HIK. The ETFs are listed according to market value of HIK within the ETF

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AstraZeneca
                  GlaxoSmithKline
                  Dechra Pharmaceuticals
                  Indivior

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis